Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma [0.03%]
SMART研究的长期临床结果：利妥昔单抗、来那度胺和伊布替尼治疗新诊断的大B细胞淋巴瘤患者
Karan L Chohan,Eduardo Edelman Saul,R Eric Davis et al.
Karan L Chohan et al.
Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma [0.03%]
CASSIOPEIA患者的表达谱 refinement了多发性骨髓瘤中MRD阴性的预后价值
Florence Magrangeas,Catherine Guérin-Charbonnel,Victor Bessonneau-Gaborit et al.
Florence Magrangeas et al.
Long-term follow-up of the CASSIOPEIA trial (NCT02541383) demonstrated superior progression-free survival (PFS) with daratumumab, both in combination with bortezomib, thalidomide, and dexamethasone during induction and consolidation, and du...
Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study [0.03%]
zanubrutinib联合R-CHOP治疗伴有特定基因异常的初治弥漫大B细胞淋巴瘤Ⅱ期临床研究
Qunling Zhang,Shiyu Jiang,Ran Wei et al.
Qunling Zhang et al.
Diffuse large B-cell lymphoma (DLBCL) remains clinically heterogeneous, and outcomes with R-CHOP are suboptimal in patients carrying high-risk genomic alterations such as MYD88, CD79B, NOTCH1, TP53 mutations or MYC rearrangements. Many of t...
Effect of anemia developed after ruxolitinib initiation on adverse outcomes in patients with myelofibrosis: a nationwide cohort study [0.03%]
鲁索利替尼治疗后发生贫血对骨髓纤维化患者不良后果的影响：一项全国队列研究
Minjeong Jeon,Yubin Lee,Jieun Woo et al.
Minjeong Jeon et al.
Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers [0.03%]
IDH1/2突变克隆在急性髓系白血病中的动态变化对其作为通用MRD标志物的适用性提出了挑战
Giovanni Marconi,Lorenza Bandini,Agnese Patuelli et al.
Giovanni Marconi et al.
Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma [0.03%]
循环CD20阳性细胞外囊泡影响弥漫性大B细胞淋巴瘤的利妥昔单抗疗效及预后预测功能
Bon Park,Kyung Ju Ryu,Min Kyu Choi et al.
Bon Park et al.
Rituximab, an anti-CD20 monoclonal antibody, is a cornerstone of therapy for diffuse large B-cell lymphoma (DLBCL), yet a substantial proportion of patients develop treatment failure. While loss of CD20 expression has been considered a majo...
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database [0.03%]
国际MDS联盟(icMDS)VALIDATE数据库中高危骨髓增生异常综合征/肿瘤患者接受低甲基化药物联合维奈克拉治疗的疗效分析
Jan Philipp Bewersdorf,Tariq Kewan,Luca Lanino et al.
Jan Philipp Bewersdorf et al.
Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus...
Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma [0.03%]
基于基线血浆的循环肿瘤DNA分析：在霍奇金淋巴瘤中比较多重数字PCR和NGS的纵向监测能力
Zahra Haider,Linn Deleskog Spångberg,Karin E Smedby et al.
Zahra Haider et al.
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia [0.03%]
成人急性淋巴细胞白血病可测量残留病灶的Inotuzumab Ozogamicin治疗
Elias Jabbour,Caitlin R Rausch,Hannah Goulart et al.
Elias Jabbour et al.
Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, has demonstrated high response rates and measurable residual disease (MRD)-negativity in acute lymphoblastic leukemia (ALL). This phase 2 single-center study evaluated inotuzumab ...
Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT [0.03%]
异基因造血干细胞移植治疗TP53突变型急性髓系白血病/骨髓增生异常综合征中，移植前后的TP53分子残留病变是复发的预后生物标志物
Yeqian Zhao,Weijie Cao,Jimin Shi et al.
Yeqian Zhao et al.